Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer

Safety and efficacy of gemcitabine plus docetaxel (GD) and capecitabine plus docetaxel (CD) were compared in patients with metastatic breast cancer, where the alternate crossover monotherapy (GD→C or CD→G) was predetermined. Patients were randomly assigned to 3-week cycles of either gemcitabine 1000...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2011-05, Vol.22 (5), p.1094-1101
Hauptverfasser:	Seidman, A.D., Brufsky, A., Ansari, R.H., Hart, L.L., Stein, R.S., Schwartzberg, L.S., Stewart, J.F., Russell, C.A., Chen, S.-C., Fein, L.E., De La Cruz Vargas, J.A., Kim, S.-B., Cavalheiro, J., Zhao, L., Gill, J.F., Obasaju, C.K., Orlando, M., Tai, D.F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Capecitabine Cross-Over Studies crossover Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Disease-Free Survival Docetaxel Female Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives gemcitabine Gynecology. Andrology. Obstetrics Humans Kaplan-Meier Estimate Mammary gland diseases Medical sciences metastatic breast cancer Middle Aged Neoplasm Metastasis Pharmacology. Drug treatments phase III Taxoids - administration & dosage Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!